Unbiased AI-powered news
9 stories related to this topic, newest first.
The U.S. Food and Drug Administration proposed withdrawing approval for Amgen's drug Tavneos on April 28, 2026, citing lack of proven effectiveness and false statements in the original application. The agency reported 76 cases of drug-induced liver injury linked to the drug, incl…
Substrate placeholder — needs reviewA recent study has identified increased copper levels in regulatory T cells among patients with rheumatoid arthritis. This finding may inform the development of new treatments for autoimmune diseases. The research highlights potential therapeutic avenues based on these observatio…
Substrate placeholder — needs reviewA woman diagnosed with an ultra-rare combination of three autoimmune diseases received a single dose of engineered immune cells. She has experienced no symptoms since the treatment. The case was reported in a medical journal.
medpagetoday.comResearchers are exploring CAR-T cell therapy's potential in treating autoimmune diseases beyond cancer. GlaxoSmithKline announced it will discontinue leucovorin, a drug used in chemotherapy support. These updates highlight ongoing advancements and changes in the biotechnology sec…
Substrate placeholder — needs reviewResearchers conducted single-cell analysis on approximately 1,000 individuals and found substantial differences in how immune cells age between sexes. The study, published in Nature Aging, links these differences to variations in autoimmune disease rates in women and cancer vulne…
Substrate placeholder — needs reviewA 47-year-old woman with severe autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid antibody syndrome received CAR-T cell therapy at University Hospital Erlangen in Germany last year. The treatment, which targets CD19 on B-cells, led to remission within wee…
Substrate placeholder — needs reviewCAR-T cell therapy, originally developed for cancer treatment, is achieving more remissions in patients with autoimmune diseases. According to STAT News, this progress has prompted additional clinical trials and investments from pharmaceutical companies.
A study has demonstrated the effectiveness of B cell rebooting in treating myasthenia gravis and other autoimmune conditions. The approach, previously tested in lupus and multiple sclerosis, involves depleting and resetting B cells. @EricTopol reported on the findings, highlighti…
Substrate placeholder — needs reviewA 47-year-old woman with three severe autoimmune diseases received experimental CAR-T cell therapy in early 2025 after nine failed treatments. The therapy, originally developed for cancer, targets problematic immune cells to induce remission. The patient has since returned to nor…